The collective net worth of Korea’s 50 Richest on the 2024 Forbes list rose slightly to US$115 billion from $106 billion, amid the country’s global chipmaking ambitions. The complete list can be found at www.forbes.com/korea, as well as in the April/May issue of Forbes Asia and the May issue of Forb
It has been revealed that the market capitalization of the domestic stock market surged by nearly 100 trillion won in the first quarter of this year.According to the corporate analysis firm Korea CXO Research Institute on April 16, the total market capitalization of 2,692 stocks, excluding preferred
Following the victory of the anti-merger faction led by brothers Lim Jong-yoon and Lim Jong-hoon, former presidents of Hanmi Pharmaceutical, in the proxy fight at the Hanmi Science shareholders’ meeting, the OCI Group declared the suspension of the merger process.OCI Holdings, the holding company of
Hanmi Group announced on March 25 that it has dismissed Lim Jong-yoon, president of Hanmi Science, and Lim Jong-hoon, president of Hanmi Pharmaceutical, effective March 25.The group stated that the two presidents caused disputes over important resolutions of the Hanmi Science board of directors, inf
Hanmi Pharmaceutical announced on March 18 that it will unwrap 10 new research projects, the most in the industry, in the American Association for Cancer Research 2024 (AACR 2024), which will run in San Diego of the United States from April 5 to 10.First, Hanmi Pharmaceutical will present the result
The legal battle between the sons of the founder of Hanmi Pharmaceutical -- Lim Jong-yoon and Lim Jong-hoon -- and the OCI Group has intensified. OCI Group holds a significant stake in Hanmi Science, the parent company of Hanmi Pharmaceutical Group. The legal battle remains on the question of integr
The ownership dispute within the Hanmi Pharmaceutical Group involving the owning family members is scheduled to be resolved at the shareholders’ meeting next month. The conflict persists between the mother-daughter duo -- Chairperson Song Young-sook, who is pushing for integration with the OCI Group
Hanmi Pharmaceutical Group’s eldest and second sons, President Lim Jong-yoon and President Lim Jong-hoon, have filed an injunction against the merger of Hanmi Group and OCI Group.President Lim Jong-yoon, through the X (formerly Twitter) account of his personal company Corey Group, announced on Jan.
Amid the resolution for the merger between the pharmaceutical giant Hanmi Pharmaceutical Group and the materials and energy-focused OCI Group, signs of a potential management dispute have emerged. This comes as a result of opposition from Lim Jong-yoon, the current CEO of Hanmi Pharmaceutical and th
Hanmi Pharmaceutical has received additional approval for the therapeutic use of the anti-cancer drug candidate Belvarafenib, which was technologically transferred to global pharmaceutical company Genentech, a member of the Roche Group (RHO).According to the Ministry of Food and Drug Safety on Jan.
GC Biopharma Corp’s eight-year endeavor has finally come to fruition as its blood product successfully enters the U.S. market. This achievement marks the first Korean blood product and the seventh new drug to receive approval from the U.S. Food and Drug Administration (FDA).On Dec. 18, GC Biopharma
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Hanmi Pharm delivered consensus-beating OP of W57.5bn for 3Q23, helped by both a higher drug (manufactured by Hanmi) sales portion at Hanmi (non-consolidated) and decreased Beijing Hanmi SG&A expense
Hanmi Pharmaceutical announced on Oct. 23 that it will participate in the pharmaceutical exhibition Convention on Pharmaceutical Ingredients (CPHI) Worldwide 2023 to be held in Barcelona, Spain, from Oct. 24 to 26, local time.Held annually in major European countries, CPHI Worldwide is the world’s l
According to a statement released on Oct. 16 on Hanmi Pharmaceutical’s English-language website, the company participated in the 2023 AACR-NCI-EORTC international academic conference held in Boston, Massachusetts, the U.S. from Oct. 11 to 15. During the conference, the company presented research res
Semiconductor equipment companies are accelerating their research and development (R&D) efforts in tandem with the commercialization of equipment for High Bandwidth Memory (HBM) processes, which is a next-generation memory semiconductor.According to industry sources on Oct. 11, Hanmi Semiconductor r
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.The bio industry has failed to rebound after the slowdown in antibody drug market growth in 2022. However, large CMOs are expected to start a turnaround, led by Alzheimer's antibody treatments, ADCs,
The legal team at Hanmi Pharmaceuticals, responsible for legal responses and consultations, has been selected among the Top 15 Best In-House Legal Teams in Asia.The global legal media outlet Asian Legal Business (ALB) annually evaluates legal organizations of companies headquartered in the Asia-Paci
Hanmi Pharmaceutical has invested US$7 million to secure 670,000 shares in Canadian biotech firm Aptose Biosciences. According to pharmaceutical industry sources on Sept. 8, Hanmi Pharmaceutical announced its decision to acquire 668,449 shares of Aptose through a stock purchase agreement. This follo
HANMI Semiconductor announced on Aug. 2 that it has commenced operation of the “Bonder Factory” to enhance the production capacity of the Dual TC Bonder, an essential piece of equipment for the production process of AI semiconductor wideband memory (HBM).The Bonder Factory has been established in Pl
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Hanmi Pharm delivered consolidated 2Q23 OP of W33.2bn, slightly below consensus, affected by: 1) the reflection of a major portion of R&D expenses; and 2) a temporary drop in the portion of merchandi